In early April, Gilead notified HIV doctors in the UK that the early access programme (EAP) for lenacapavir would now be closed to new participants. However, people already enrolled will be able to continue to access free drugs.
BHIVA responded with social media posts and a statement to all members.
Lenacapavir was approved in 2022 as a treatment for people with multiple drug resistance (MDR). The EAP was set up for the small number of people who urgently needed access while discussions about pricing were still ongoing.
Read the full news story at HIV i-Base.
Source : HIV i-Base
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.